Despite recent advances in antimicrobial therapy, surgical techniques, and management of the critically ill, infective endocarditis (IE) continues to command a high mortality rate. The advent of several endovascular devices (cardiac implantable electronic devices, transcatheter aortic valves, ventricular assist devices (VAD), aortic conduits, and total artificial hearts) has given a new lease of life to many patients. At the same time, these devices pose novel challenges pertaining to endovascular, graft, and device infections.
| INTRODUC TI ON
Despite recent advances in antimicrobial therapy, surgical techniques, and management of the critically ill, infective endocarditis (IE) continues to command a high mortality rate. The advent of several endovascular devices (cardiac implantable electronic devices, transcatheter aortic valves, ventricular assist devices (VAD), aortic conduits, and total artificial hearts) has given a new lease of life to many patients. At the same time, these devices pose novel challenges pertaining to endovascular, graft, and device infections.
Hardware implantation in an area of active infection violates one of the fundamental principles of surgery and infectious diseases. However, the risk of prosthetic valve endocarditis after valve implantation in an area of active native valve endocarditis is low (between 2%-10%) if the patient receives a full course of pathogendirected antimicrobial therapy after surgery. [1] [2] [3] Active infection in the recipient has traditionally been considered a contraindication for elective organ transplantation given concerns of worsening infection following immunosuppression. However, HT is curative for patients with persistent LVAD infection (driveline/pocket/pump), as the infected hardware is completely removed, despite subsequent immunosuppression. In uncontrolled studies, outcomes after heart transplantation have not differed for LVAD patients with and without LVAD infection before transplant. 4, 5 Hence, can HT represent a last-resort salvage option for patients with recurrent, refractory IE in whom valve replacement is not a feasible option, given that the infected heart is explanted at the time of HT?
The very first successful report of HT for 'intractable' prosthetic valve endocarditis was reported from Boston in 1990. 6 Since then, there have been a total of 19 published cases of severe and refractory endocarditis in whom HT has been successfully undertaken.
The primary purpose of our paper is to draw attention to the possibility of HT in patients with active IE as a life-saving measure, to discuss existing literature while emphasizing the fact that more rigorous study is necessary, to suggest general criteria for HT for IE, and to encourage professional societies to address HT and IE in their upcoming reviews and guidelines. , and Medline ® databases were queried (last updated search May 10, 2018 ) to identify publications addressing IE and heart transplantation. Search terms included "infective endocarditis," "endocarditis," "heart transplant," "heart transplantation," "transplant," and "transplantation." The search was independently repeated and verified by a qualified librarian using the same search engines and criteria. We included the English language articles involving human subjects 18 years of age or older.
| ME THODS
References cited by published reports were carefully reviewed in an effort to identify additional cases not detected using our search criteria. Only cases with active IE at the time of HT (based on intraoperative findings, explant histopathology, or clinical course leading up to HT) were included. We also included patients who were managed with temporary mechanical circulatory support such as an Impella ® device or extracorporeal membranous oxygenation (ECMO). We excluded cases of IE in whom patients were bridged to transplant with a left ventricular assist device or total artificial heart beyond the index hospitalization.
| RE SULTS
Nineteen unique cases of heart transplantation in the setting of active IE derived from 14 publications were included in our analysis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The median age was 44 years (23-64 years). Sixteen (84%) were male. Median time from diagnosis of IE to HT was 75 days (Range 23-840 days). The median time to HT in patients with staphylococcal IE was 51 days (Range 30-67 days).
Overall, patients had few underlying comorbidities. Eleven patients (58%) had cardiac comorbidities, five of whom also had non cardiac comorbidities. Five patients (26%) had non cardiac comorbidities only. Three patients (16%) were previously healthy. Noncardiac comorbidities included smoking (three patients), diabetes mellitus (two patients), alcoholism, prostate cancer, and periodontal disease (one patient each). Three patients had multisystem disorders with cardiovascular manifestations, including systemic lupus erythematosus (SLE), Marfan's syndrome, and Trisomy 9. Details are summarized in Table 1 .
One patient had prior aortic valve replacement for marantic endocarditis secondary to SLE. 6 Remote IE was noted in two other cases. One of these cases had a history of mitral valve replacement for rheumatic mitral regurgitation. 18 The other had prior IE requiring aortic and mitral valve replacement and is described in more detail below. 17 One patient had a diagnosis of hypertrophic cardiomyopathy, second-degree heart block, and pulmonary hypertension. 12 There were three other patients with congenital anomalies, including trisomy 9, congenital bicuspid aortic valve, and Marfan's syndrome. 7, 8, 15 Two patients had an ischemic cardiomyopathy, one of whom also had diabetes, hypertension, and hyperlipidemia. This patient was listed for HT at the time of diagnosis of IE. The other patient had undergone prior HT. 10, 13 One patient had a nonischemic cardiomyopathy and coexisting heparin-induced thrombocytopenia. 11 Finally, one patient had a history of a valved conduit for aortic stenosis, an ascending aortic aneurysm complicated by decreased systolic function, and complete heart block requiring pacemaker placement. He also had a history of prostate cancer. 9 Eleven patients (58%) had native valve endocarditis (NVE), six patients (32%) had prosthetic valve endocarditis (PVE) (two were mechanical prostheses, one was a bioprosthetic valve, and two prosthetic valves were not specified). Two patients (10%) had IE associated with a cardiac implantable electronic device (CIED). Four patients had an aortic conduit with a prosthetic aortic valve. The aortic valve was involved in 13 (68%) cases, mitral in 9 (47%), and tricuspid in 3 (16%); seven patients had multivalvular IE. 5 years post-HT due to IE relapse. 15 A third patient was placed on chronic antifungal therapy due to postoperative Candida albicans infection. 13 Both of these cases are described in more detail below.
In two cases, antibiotics were stopped post-transplant due to negative intraoperative cultures and in five cases, duration of treatment post-HT was not reported. When antimicrobials were administered post-transplant, the minimum duration was 14 days. Details of microbiology, histopathology, and antimicrobial therapy are summarized in Table 2 .
In all published reports, patients with HT for IE had good outcomes and were alive at the time of case publication. Median and working as an accountant 6 years post-transplant. 13 Details are summarized in Table 3 . Even though active infection is considered a contraindication to HT, 23 it does not apply to LVAD-associated infections, as HT is curative in this situation. 24 The risk of infection following HT in the setting of LVAD infection was evaluated in 149 patients who had received LVAD implantation as a bridge to transplant. 4 The primary a high mortality rate with a 1-year survival of only 55% and 2-year survival of 34%. 5 Even though these studies were not prospective controlled trials, they provide some reassurance and cautious optimism for the success of HT in patients with refractory IE.
| D ISCUSS I ON
Another consideration for patients with active, destructive IE and severely depressed ventricular function might be to bridge with mechanical circulatory support devices. Two cases in which a total artificial heart (TAH) and LVAD were utilized in patients with acute IE as a bridge, followed by HT several months later have been described with good outcomes. 25, 26 The first patient had a background of repaired coarctation of the aorta, bicuspid aortic valve, and subsequent aortic stenosis. 25 She underwent bioprosthetic aortic valve replacement and root enlargement age was weaned, pathogen-directed antimicrobials were initiated, and the patient was successfully bridged to HT 6 months later.
The patient was alive and without complications during 7-month follow-up. 25 The second case involves a patient with Tropheryma whipplei endocarditis. 26 He presented with an anterior ST segment as an option for refractory IE. 27 The 2016 American Association of Thoracic Surgery (AATS) guidelines also make no mention of any role for HT in patients with IE. 28 The 2015 European Society 
